Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.
Claudin-18.2
Esophageal cancer
Gastric cancer
Gastroesophageal junction cancer
Immunotherapy
Programmed cell death ligand 1
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
accepted:
10
12
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
21
12
2023
Statut:
aheadofprint
Résumé
Cancers of the upper gastrointestinal tract represent a lethal disease entity comprising the esophagus, gastroesophageal junction, and stomach. The backbone of therapy in esophagogastric cancers has predominantly been chemotherapy-based. However, over the last decade, with the debut of immune checkpoint inhibitors, sophisticated molecular testing, and a more comprehensive understanding of the tumor microenvironment, immunotherapy has been incorporated into the treatment of localized and advanced esophagogastric cancers with promising results. This study aimed to review the unique tumor microenvironment and role of immunotherapy in esophagogastric cancers. We conducted a systematic review of clinical and translational research for immunotherapy in esophagogastric cancers. This article will explore the unique tumor microenvironment in gastroesophageal cancers, the role of immunotherapy in localized and advanced disease, challenges in management, and new therapeutic approaches in clinical trials. With further exploration into targeted therapy and immunotherapy, we anticipate the emergence of novel treatments that will improve survival and quality of life in patients with esophagogastric cancers.
Sections du résumé
BACKGROUND
BACKGROUND
Cancers of the upper gastrointestinal tract represent a lethal disease entity comprising the esophagus, gastroesophageal junction, and stomach. The backbone of therapy in esophagogastric cancers has predominantly been chemotherapy-based. However, over the last decade, with the debut of immune checkpoint inhibitors, sophisticated molecular testing, and a more comprehensive understanding of the tumor microenvironment, immunotherapy has been incorporated into the treatment of localized and advanced esophagogastric cancers with promising results.
PURPOSE
OBJECTIVE
This study aimed to review the unique tumor microenvironment and role of immunotherapy in esophagogastric cancers.
METHODS
METHODS
We conducted a systematic review of clinical and translational research for immunotherapy in esophagogastric cancers.
RESULTS
RESULTS
This article will explore the unique tumor microenvironment in gastroesophageal cancers, the role of immunotherapy in localized and advanced disease, challenges in management, and new therapeutic approaches in clinical trials.
CONCLUSION
CONCLUSIONS
With further exploration into targeted therapy and immunotherapy, we anticipate the emergence of novel treatments that will improve survival and quality of life in patients with esophagogastric cancers.
Identifiants
pubmed: 38127239
doi: 10.1007/s12029-023-01000-8
pii: 10.1007/s12029-023-01000-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Wang DK, Zuo Q, He QY, Li B. Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications. Front Immunol. 2021;12:705999.
doi: 10.3389/fimmu.2021.705999
pubmed: 34447376
pmcid: 8383067
Shimozaki K, Nakayama I, Hirota T, Yamaguchi K. Current strategy to treat immunogenic gastrointestinal cancers: perspectives for a new era. Cells. 2023;12(7).
Sidaway P. Immunotherapy-responsive gastric cancers identified. Nat Rev Clin Oncol. 2018;15(10):590-.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
doi: 10.1056/NEJMoa1112088
pubmed: 22646630
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191–203.
doi: 10.1056/NEJMoa2032125
pubmed: 33789008
Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol (London, England). 2021;17(10):1143–53.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
doi: 10.1056/NEJMoa055531
pubmed: 16822992
Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392–400.
doi: 10.1200/JCO.19.01124
pubmed: 31513484
Nie RC, Chen GM, Yuan SQ, Kim JW, Zhou J, Nie M, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: Systematic Review and Meta-Analysis. Ann Surg Oncol. 2022;29(4):2324–31.
doi: 10.1245/s10434-021-11050-6
pubmed: 34796431
André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255–65.
doi: 10.1200/JCO.22.00686
pubmed: 35969830
Pietrantonio F, Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol. 2023;41(4_suppl):358-.
Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future oncology (London, England). 2019;15(9):943–52.
doi: 10.2217/fon-2018-0581
pubmed: 30777447
Al-Batran S-E, Lorenzen S, Thuss-Patience PC, Homann N, Schenk M, Lindig U, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol. 2022;40(16_suppl):4003-.
Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future oncology (London, England). 2022;18(20):2465–73.
doi: 10.2217/fon-2022-0093
pubmed: 35535555
Shitara K. LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study. Ann Oncol. 2023;34.
Al-Batran S-E, Lorenzen S, Thuss-Patience PC, Homann N, Schenk M, Lindig U, et al. A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK. J Clin Oncol. 2023;41(16_suppl):TPS4177-TPS.
Janjigian. LBA73 - Pathological complete response (pCR) to durvalumabplus 5-fl uorouracil, leucovorin, oxaliplatin and docetaxel(FLOT) in resectable gastric and gastroesophageal junctioncancer (GC/GEJC): Interim results of the global, phase IIIMATTERHORN study. Ann Oncol. 2023.
Data are still insufficient to recommend immune checkpoint inhibitors in perioperative therapy for gastric/gastro-oesophageal junction cancers [cited 2023]. Available from: https://dailyreporter.esmo.org/esmo-congress-2023/gastrointestinal-cancers/data-are-still-insufficient-to-recommend-immune-checkpoint-inhibitors-in-perioperative-therapy-for-gastric-gastro-oesophageal-junction-cancers .
Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23(1):95–104.
doi: 10.1007/s10120-019-00999-9
pubmed: 31451991
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.
doi: 10.1001/jamaoncol.2018.0013
pubmed: 29543932
pmcid: 5885175
FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-advanced-gastric-cancer .
Tucker N. Pembrolizumab withdrawn from US market as option for third-line gastric or GEJ adenocarcinoma. 2021 [November 19, 2023]. Available from: https://www.targetedonc.com/view/pembrolizumab-withdrawn-from-us-market-as-option-for-third-line-gastric-or-gej-adenocarcinoma .
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 2011;108(17):7142–7.
doi: 10.1073/pnas.1016569108
pubmed: 21482773
pmcid: 3084100
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30.
doi: 10.1038/s41586-021-04161-3
pubmed: 34912120
pmcid: 8959470
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023.
FDA amends pembrolizumab’s gastric cancer indication. 2023. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication .
EMA adopts a positive opinion for a new indication for pembrolizumab. 2023. Available from: https://www.esmo.org/oncology-news/ema-adopts-a-positive-opinion-for-a-new-indication-for-pembrolizumab .
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.
doi: 10.1016/S0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782
Janjigian YY, Shitara K, Moehler MH, Garrido M, Gallardo C, Shen L, et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. J Clin Oncol. 2023;41(4_suppl):291-.
Opdivo: European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo .
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines): esophageal and esophagogastric junction cancers. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf . Accessed on 19 Dec 2023.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.
FDA approves pembrolizumab for esophageal or GEJ carcinoma. 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma .
European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda .
Tabernero J, Bang YJ, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, et al. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Future Oncol (London, England). 2021;17(22):2847–55.
doi: 10.2217/fon-2021-0176
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181–95.
doi: 10.1016/S1470-2045(23)00515-6
pubmed: 37875143
Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–80.
doi: 10.1001/jamaoncol.2020.3370
pubmed: 32880601
Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392–402.
doi: 10.1200/JCO.21.01862
pubmed: 34860570
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–62.
doi: 10.1056/NEJMoa2111380
pubmed: 35108470
Kato K, Ajani JA, Doki Y, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. J Clin Oncol. 2023;41(4_suppl):290-.
Chao I. Abstract: O-3 Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. Ann Oncol. 2022;33.
Opdivo-nivolumab injection. 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394 .
Yervoy: ipilimumab injection. 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66 .
Yap DWT, Leone AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, et al. Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups. JAMA Oncol. 2023;9(2):215–24.
doi: 10.1001/jamaoncol.2022.5816
pubmed: 36480211
Wu HX, Pan YQ, He Y, Wang ZX, Guan WL, Chen YX, et al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J Clin Oncol. 2023;41(9):1735–46.
doi: 10.1200/JCO.22.01490
pubmed: 36473145
Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. 2022;8(10):1456–65.
doi: 10.1001/jamaoncol.2022.3707
pubmed: 36006624
pmcid: 9412834
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–8.
doi: 10.1038/s41586-022-04508-4
pubmed: 35322232
pmcid: 8967713
Yoon HH, Dong H, Shi Q. Impact of PD-1 blockade in nonresponders: pitfalls and promise. Clin Cancer Res. 2022;28(15):3173–5.
doi: 10.1158/1078-0432.CCR-22-0932
pubmed: 35671005
pmcid: 9357158
Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895–902.
doi: 10.1001/jamaoncol.2021.0275
pubmed: 33792646
pmcid: 8017478
Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929–38.
doi: 10.1016/j.annonc.2022.05.519
pubmed: 35680043
Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, et al. High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma. Mod Pathol. 2023;36(5): 100154.
doi: 10.1016/j.modpat.2023.100154
pubmed: 36925069
Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26(24):6453–63.
doi: 10.1158/1078-0432.CCR-20-2085
pubmed: 32820017
pmcid: 7744325
Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, et al. Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int. 2020;20:186.
doi: 10.1186/s12935-020-01273-0
pubmed: 32489322
pmcid: 7247123
Pihlak R, Fong C, Starling N. Targeted therapies and developing precision medicine in gastric cancer. Cancers (Basel). 2023;15(12).
Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.
doi: 10.1038/s41591-018-0101-z
pubmed: 30013197
Nakano H, Saito M, Nakajima S, Saito K, Nakayama Y, Kase K, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Sci Rep. 2021;11(1):1982.
doi: 10.1038/s41598-021-81667-w
pubmed: 33479394
pmcid: 7820576
Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
doi: 10.1038/nature13480
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56.
doi: 10.1038/nm.3850
pubmed: 25894828
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, et al. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11(7):824–46.
doi: 10.1002/1878-0261.12093
pubmed: 28614624
pmcid: 5496499
Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13(1):4851.
doi: 10.1038/s41467-022-32570-z
pubmed: 35982052
pmcid: 9388563
Haas MS, Kagey MH, Heath H, Schuerpf F, Rottman JB, Newman W. mDKN-01, a novel anti-DKK1 mAb, enhances innate immune responses in the tumor microenvironment. Mol Cancer Res. 2021;19(4):717–25.
doi: 10.1158/1541-7786.MCR-20-0799
pubmed: 33443105
Klempner SJ, Sonbol BB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, et al. A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). J Clin Oncol. 2023;41(16_suppl):4027-.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655–68.
Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–41.
Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2023;29(19):3882–91.
Zhang M, Gong J, Wang J, Shi J, Zhu H, Wang Y, et al. A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors. J Clin Oncol. 2023;41:397-.
A trial to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of TST001 in advanced or metastatic solid tumors. ClinicalTrials.gov identifier: NCT04495296. Updated March 3, 2023. Accessed on 19 Dec 2023. https://www.clinicaltrials.gov/study/NCT04495296?term=NCT04495296&rank=1 .
A trial to evaluate safety and tolerability of TST001 in advanced or metastatic solid tumors. ClinicalTrials.gov identifier: NCT04396821. Updated December 13, 2023. Accessed on 19 Dec 2023. https://www.clinicaltrials.gov/study/NCT04396821?term=NCT04396821&rank=1 .
Gao J, Wang Z, Jiang W, Zhang Y, Meng Z, Niu Y, et al. CLDN18.2 and 4–1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023;11(6).
I-Mab announces first patient dosed in phase 1 clinical trial of Claudin 18.2 and 4–1BB bispecific antibody TJ-CD4B in solid tumors in China: I-Mab Biopharma. 2022. Available from: https://www.i-mabbiopharma.com/i-mab-announces-first-patient-dosed-in-phase-1-clinical-trial-of-claudin-18-2-and-4-1bb-bispecific-antibody-tj-cd4b-in-solid-tumors-in-china/ .
Study of TJ033721 in subjects with advanced or metastatic solid tumors. ClinicalTrials.gov identifier NCT04900818. Updated June 22, 2023. Accesed on 19 Dec 2023. https://clinicaltrials.gov/study/NCT04900818?cond=TJ033721&rank=1#study-plan .
PT886 for treatment of patients with advanced gastric, gastroesophageal junction and pancreatic adenocarcinomas. ClinicalTrials.gov identifier: NCT05482893. Updated June 15, 2023. Accessed on 19 Dec 2023. https://clinicaltrials.gov/study/NCT05482893?term=NCT05482893&rank=1 .
Xu R. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors. J Clin Oncol. 2023;41(4_suppl):352-.
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189–98.
Botta GP, Becerra CR, Jin Z, Kim DW, Zhao D, Lenz H-J, et al. Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma. J Clin Oncol. 2022;40(16_suppl):2538-.
Janjigian YY, Oh D-Y, Pelster M, Wainberg ZA, Sison EAR, Scott JR, et al. EDGE-Gastric Arm A1: phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer. J Clin Oncol. 2023;41(36_suppl):433248-.
A clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body (STAR-221).
Wainberg ZA, Enzinger PC, Kang Y-K, Yamaguchi K, Qin S, Lee K-W, et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). J Clin Oncol. 2021;39(3_suppl):160-.
Xiang H, Chan AG, Ahene A, Bellovin DI, Deng R, Hsu AW, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021;13(1):1981202.
doi: 10.1080/19420862.2021.1981202
pubmed: 34719330
pmcid: 8565817
Wainberg ZA, Cutsem EV, Moehler MH, Kang Y-K, Yen P, Finger E, et al. Trial in progress: phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102). J Clin Oncol. 2022;40(16_suppl):TPS4165-TPS.
Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron. 2015;2(1).
Yanez PE, Ben-Aharon I, Rojas C, Eyzaguirre DA, Hubert A, Araya H, et al. First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): safety run-in results. J Clin Oncol. 2023;41(4_suppl):411-.